Menu
Search
|

Menu

Close
X

Evofem Biosciences Inc EVFM.OQ (NASDAQ Stock Exchange Capital Market)

2.52 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 2.52
Open --
Volume --
3m Avg Volume 12,047
Today’s High --
Today’s Low --
52 Week High 12.84
52 Week Low 1.80
Shares Outstanding (mil) 26.26
Market Capitalization (mil) 66.18
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-4.616
FY17
-6.168
FY16
-5.664
FY15
-18.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
--
8.04
Price to Book (MRQ)
vs sector
--
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
--
17.43
LT Debt to Equity (MRQ)
vs sector
--
13.25
Return on Investment (TTM)
vs sector
--
13.23
Return on Equity (TTM)
vs sector
--
15.27

EXECUTIVE LEADERSHIP

Saundra Pelletier
Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Justin File
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Maria Feldman
Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance, Since 2016
Salary: --
Bonus: --
Alexander Fitzpatrick
General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Russell Barrans
Chief Commercial Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

12400 High Bluff Dr Ste 600
SAN DIEGO   CA   92130-3077

Phone: +1858.5501900

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is an injectable formulation of the long-acting Beta2-adrenergic receptor agonist, and salmeterol xinafoate, which is an active ingredient in the United States Food and Drug Administration inhaled products, such as SEREVENT DISKUS, ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.

SPONSORED STORIES